Anticoagulation in Patients with AF with GI Bleeding

Duration

15 mins

Profession

Physician

# of Credits

0.25

Accreditation

Mainpro+

Expiry Date

2022-09-20

Direct oral anticoagulants (DOACs) have been shown to significantly reduce the risk of stroke in patients with atrial fibrillation (AF). Each of the four DOACs available in Canada has its own absorption properties that can help determine the most appropriate choice for anticoagulation. In this expert brief, Dr. Green and Dr Habert will briefly review the evidence and differentiate the DOACs on their respective risks of gastrointestinal (GI) bleeding in patients with AF. They will also discuss strategies to reinforce importance of compliance for patients who have experienced a GI bleeding, review when it is safe to restart the DOAC after GI bleeding, and examine the potential role of proton pump inhibitors to reduce the risk of a GI bleed.


This program is made possible through educational support from the BMS/Pfizer Alliance.

This self-learning program has been certified by the College of Family Physicians of Canada for up to 0.25 Mainpro+ credits.

Cert+ Program ID#: 194874

N/A

Daniel Green, MD, FRCPC

Jeffrey Habert, MD

Anas Nsier, MD

Sy Lam, MD, CCFP, FCFP

Parmjit Sohal, MD, PhD, CCFP, FCFP

Upon completion of this continuing education program, participants will be better able to:

  • Describe the evidence and differentiate the various direct oral anticoagulants (DOACs) on risk of gastrointestinal (GI) bleeding in patients with atrial fibrillation (AF);
  • Discuss strategies to reinforce importance of compliance for patients who have experienced a GI bleeding;
  • Review when it is safe to restart DOAC after GI bleeding in AF;
  • Explain the potential role of PPIs to reduce the risk of a GI bleed.